Antimicrobial Agents Practice Questions

Q: Nightmares are commonly associated with which of the following antiretroviral drugs?

Efavirenz. **Explanation:** **Efavirenz** is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) that is notorious for causing **central nervous system (CNS) side effects** in up to 50% of patients. These symptoms typically occur during the first few weeks of treatment and include **vivid dreams, nightmares**, insomnia, dizziness, and "hangover" sensations. In severe cases, it can lead to depression or psychosis. These effects are attributed to the drug's ability to cross the blood-brain barrier and its structural similarity to certain psychoactive compounds. **Analysis of Incorrect Options:** * **Indinavir (Protease Inhibitor):** Primarily associated with **nephrolithiasis** (kidney stones) due to crystalluria and metabolic side effects like insulin resistance and lipodystrophy. * **Zidovudine (NRTI):** The hallmark side effect is **bone marrow suppression** (anemia and neutropenia) and myopathy. It does not typically cause neuropsychiatric symptoms. * **Tenofovir (NRTI):** Most commonly associated with **nephrotoxicity** (Fanconi syndrome) and a decrease in bone mineral density. **High-Yield Clinical Pearls for NEET-PG:** * **Administration Tip:** Efavirenz should be taken on an **empty stomach at bedtime** to reduce the peak plasma concentration and minimize the severity of CNS side effects. * **Teratogenicity:** Efavirenz was historically avoided in the first trimester of pregnancy due to concerns regarding **neural tube defects**, though recent guidelines have relaxed this restriction. * **Metabolism:** It is a potent inducer of CYP3A4 enzymes, leading to numerous drug-drug interactions.

Q: What are the differences between fluconazole and ketoconazole?

All the above. The correct answer is **D. All the above**. Fluconazole and ketoconazole are both azole antifungals, but they belong to different subclasses (Triazoles vs. Imidazoles) and possess distinct pharmacokinetic and safety profiles. **1. Duration of Action (Half-life):** Fluconazole has a significantly longer half-life (~30 hours), allowing for once-daily dosing. In contrast, ketoconazole has a shorter half-life (~7–10 hours) and often requires more frequent administration. **2. Absorption Dependency on Gastric Acidity:** Ketoconazole requires an acidic environment for dissolution and absorption; its bioavailability is reduced by antacids, H2 blockers, or proton pump inhibitors. Fluconazole absorption is independent of gastric pH and is nearly 100% bioavailable after oral administration. **3. Adverse Effects:** Ketoconazole is a potent inhibitor of mammalian cytochrome P450 enzymes, leading to significant drug interactions and **anti-androgenic effects** (gynecomastia, loss of libido, menstrual irregularities) due to inhibition of steroid synthesis. It also carries a higher risk of hepatotoxicity. Fluconazole is much more selective for fungal enzymes and lacks these anti-androgenic side effects. **High-Yield Clinical Pearls for NEET-PG:** * **CSF Penetration:** Fluconazole has excellent CNS penetration (useful for Cryptococcal meningitis), whereas ketoconazole penetrates poorly. * **Excretion:** Fluconazole is primarily excreted unchanged in the urine (useful for fungal UTIs); ketoconazole is metabolized by the liver. * **Endocrine Use:** Due to its side effect profile, ketoconazole is sometimes used therapeutically to treat **Cushing’s syndrome** (inhibits cortisol synthesis). * **Drug of Choice:** Fluconazole is the DOC for *Candida albicans* infections.

Q: Bleeding is seen with the use of which of the following drugs?

Moxalactam. **Explanation:** The correct answer is **Moxalactam**. **Mechanism of Bleeding:** Certain cephalosporins and related beta-lactams (like Moxalactam) contain a **Methylthiotetrazole (MTT) side chain**. This side chain is responsible for two major adverse effects: 1. **Hypoprothrombinemia:** The MTT group inhibits Vitamin K epoxide reductase, interfering with the synthesis of Vitamin K-dependent clotting factors (II, VII, IX, and X), leading to an increased risk of bleeding. 2. **Disulfiram-like reaction:** It inhibits aldehyde dehydrogenase, causing intolerance to alcohol. Additionally, Moxalactam can cause bleeding by interfering with **platelet aggregation**. **Analysis of Options:** * **Moxalactam (Correct):** A carbacephem (often grouped with 3rd gen cephalosporins) that possesses the MTT side chain and is notorious for causing severe bleeding episodes. * **Cefaloridine:** A 1st generation cephalosporin primarily known for its dose-dependent **nephrotoxicity** (acute tubular necrosis), not bleeding. * **Cefazolin:** A 1st generation cephalosporin commonly used for surgical prophylaxis. While it is the drug of choice for many procedures, it does not typically cause bleeding (though it has a related structure, the clinical incidence is negligible compared to Moxalactam). * **Ceftazidime:** A 3rd generation cephalosporin with excellent activity against *Pseudomonas*. It does not contain the MTT side chain and is not associated with bleeding. **High-Yield NEET-PG Pearls:** * **MTT Side Chain Drugs:** Remember the mnemonic **"MAN":** **M**oxalactam, **A**f (Cefamandole), **N** (Cefoperazone, Cefotetan). * **Management:** Bleeding caused by these drugs can be prevented or reversed by administering **Vitamin K**. * **Nephrotoxicity:** Cefaloridine is the most nephrotoxic; Ceftriaxone is known for biliary sludge/pseudolithiasis.

Q: What is the drug of choice for a sore throat caused by Group A beta-hemolytic Streptococcus?

Penicillin. **Explanation:** **1. Why Penicillin is the Correct Answer:** Group A beta-hemolytic Streptococcus (GABHS), specifically *Streptococcus pyogenes*, remains exquisitely sensitive to **Penicillin**. It is the drug of choice (DOC) because of its narrow spectrum, low cost, and proven efficacy in preventing non-suppurative complications like **Acute Rheumatic Fever (ARF)**. For oral therapy, **Penicillin V** (Phenoxymethylpenicillin) is preferred; however, a single intramuscular injection of **Benzathine Penicillin G** is often used to ensure compliance. **2. Why Other Options are Incorrect:** * **Erythromycin (Option A):** This is the first-line alternative only for patients with a **documented penicillin allergy**. It is not the primary DOC due to increasing resistance among Streptococci. * **Ceftriaxone (Option C):** While effective, this is a broad-spectrum third-generation cephalosporin. Using it for simple pharyngitis violates antibiotic stewardship and is unnecessary given the high sensitivity to Penicillin. * **Sulfonamides (Option D):** These are bacteriostatic and are **not effective** in eradicating GABHS from the pharynx. They do not prevent the development of Acute Rheumatic Fever. **3. NEET-PG High-Yield Clinical Pearls:** * **Eradication Goal:** The primary goal of treating GABHS pharyngitis is the prevention of **Acute Rheumatic Fever**, not necessarily Post-Streptococcal Glomerulonephritis (PSGN), as antibiotics do not significantly reduce the risk of PSGN. * **Resistance:** To date, there has never been a documented case of clinical resistance of *S. pyogenes* to Penicillin. * **Diagnosis:** In clinical practice, the **Centor Criteria** are used to determine the likelihood of bacterial vs. viral sore throat.

Q: The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivatives (artemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except?

Artesunate plus quinine. **Explanation:** The World Health Organization (WHO) recommends **Artemisinin-based Combination Therapy (ACT)** as the first-line treatment for uncomplicated *P. falciparum* malaria. The rationale behind ACT is to combine a fast-acting artemisinin derivative (to rapidly reduce parasite biomass) with a long-acting partner drug (to eliminate remaining parasites and prevent resistance). **Why Option B is correct:** **Artesunate plus Quinine** is not a recommended ACT. Quinine is a rapidly acting schizonticide with a short half-life, similar to artemisinin derivatives. Combining two short-acting drugs violates the principle of ACT, as there is no long-acting "partner" to provide a tail of protection, leading to poor compliance (due to quinine's 7-day regimen) and higher recrudescence rates. Quinine is typically reserved for severe malaria or as a second-line treatment in specific combinations (e.g., with clindamycin or doxycycline). **Analysis of Incorrect Options:** * **Option A (Artemether + Lumefantrine):** The most widely used fixed-dose ACT globally (Coartem). * **Option C (Artesunate + Sulfadoxine-Pyrimethamine):** A recommended ACT, though its use is limited in areas with high high-level SP resistance. * **Option D (Artesunate + Mefloquine):** A standard ACT frequently used in Southeast Asia and South America. **High-Yield NEET-PG Pearls:** 1. **First-line ACT in India:** Artesunate + Sulfadoxine-Pyrimethamine (AS+SP) is used nationwide, **except** in North-Eastern states where resistance is high; there, **Artemether + Lumefantrine** is the drug of choice. 2. **Pregnancy:** ACTs are now recommended for uncomplicated malaria in **all trimesters** of pregnancy. 3. **Severe Malaria:** IV Artesunate is the drug of choice (superior to Quinine). 4. **Mechanism:** Artemisinins act by releasing free radicals via the cleavage of their endoperoxide bridge.

Q: Toxicity of amphotericin B can be reduced by which of the following methods?

Incorporation into a liposomal complex. **Explanation:** **Amphotericin B** is a potent antifungal that acts by binding to ergosterol in fungal cell membranes, creating pores. However, it also binds to cholesterol in human cell membranes, leading to significant toxicities, most notably **nephrotoxicity** (azotemia, renal tubular acidosis, and electrolyte wasting). **Why Option C is Correct:** The incorporation of Amphotericin B into **liposomal complexes** (Liposomal Amphotericin B or L-AMB) is the gold standard for reducing toxicity. The lipid vehicle acts as a reservoir, sequestering the drug from human cells (like renal tubular cells) while preferentially delivering it to the site of infection where fungal lipases release the active drug. This significantly reduces nephrotoxicity and infusion-related reactions (fever, chills). **Why Other Options are Incorrect:** * **Option A:** Amphotericin B is physically incompatible with saline (it precipitates) and must be reconstituted in **5% Dextrose**. While necessary for administration, using dextrose does not reduce the drug's inherent toxicity. * **Option B:** Combining Amphotericin B with Fluconazole is generally avoided. Azoles inhibit the synthesis of ergosterol, which is the target for Amphotericin B. Therefore, Fluconazole can theoretically decrease the efficacy of Amphotericin B rather than reducing its toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Dose-limiting toxicity:** Nephrotoxicity (permanent damage is related to the cumulative dose). * **Electrolyte abnormalities:** Hypokalemia and Hypomagnesemia are classic side effects. * **Pre-medication:** To prevent "shake and bake" infusion reactions, patients are often pre-treated with NSAIDs, antihistamines, or hydrocortisone. * **Lipid Formulations:** Include L-AMB (AmBisome), ABCD (Colloidal dispersion), and ABLC (Lipid complex). L-AMB is the least toxic.

Q: Which of the following antimicrobial agents is not effective against anaerobes?

Gentamicin. **Explanation:** The correct answer is **Gentamicin**. **1. Why Gentamicin is the correct answer:** Gentamicin is an **Aminoglycoside**. The fundamental mechanism of aminoglycoside uptake into bacterial cells is an **oxygen-dependent active transport** process. In anaerobic environments, bacteria lack the oxygen-linked electron transport chain required to pump the drug across the cytoplasmic membrane. Consequently, aminoglycosides cannot reach their target (the 30S ribosome) in anaerobic bacteria, rendering them inherently resistant [2]. **2. Why the other options are incorrect:** * **Cefotetan:** This is a second-generation cephalosporin (specifically a cephamycin). Cephamycins are unique among cephalosporins for having significant activity against Gram-negative anaerobes, including *Bacteroides fragilis*. * **Imipenem:** This is a Carbapenem. Carbapenems possess the broadest spectrum of activity among beta-lactams and are highly effective against almost all clinically significant anaerobes [3]. * **Clindamycin:** This is a Lincosamide. It is a classic anti-anaerobic agent, particularly effective against anaerobes "above the diaphragm" (e.g., *Fusobacterium*, *Prevotella*). **Clinical Pearls for NEET-PG:** * **Mnemonic:** "Aminoglycosides require **O2** to go through the **DOOR**." (Oxygen-dependent uptake). * **Drug of Choice for Anaerobes:** * **Below the diaphragm** (e.g., *B. fragilis*): Metronidazole. * **Above the diaphragm** (e.g., dental infections): Clindamycin. * **Synergy:** Aminoglycosides are often combined with Cell Wall Synthesis Inhibitors (like Penicillins) because the latter break down the cell wall, facilitating drug entry even in relatively low-oxygen environments (used in treating Enterococcal endocarditis) [1].

Q: Which of the following is a broad-spectrum antibiotic?

Tetracycline. ### Explanation **Correct Answer: C. Tetracycline** **Underlying Medical Concept:** In pharmacology, antibiotics are classified based on their **spectrum of activity**. **Broad-spectrum antibiotics** are effective against a wide range of microorganisms, including both Gram-positive and Gram-negative bacteria, as well as atypical organisms like Rickettsia, Chlamydia, and Mycoplasma. **Tetracyclines** are the classic example of broad-spectrum agents because they inhibit protein synthesis (by binding to the 30S ribosomal subunit) across a diverse array of bacterial species. **Analysis of Options:** * **A. Erythromycin:** This is a **narrow-spectrum** macrolide. Its activity is primarily restricted to Gram-positive bacteria and a few Gram-negative cocci (like Neisseria). It is often used as an alternative in penicillin-allergic patients. * **B. Streptomycin:** This is an aminoglycoside with a **narrow spectrum**, primarily targeting aerobic Gram-negative bacilli and *Mycobacterium tuberculosis*. It lacks significant activity against Gram-positive organisms and anaerobes. * **D. All of the above:** Incorrect, as only Tetracycline meets the criteria for a broad-spectrum agent in this list. **NEET-PG High-Yield Pearls:** * **Broad-spectrum examples:** Tetracyclines, Chloramphenicol, and newer Cephalosporins (3rd/4th generation). * **Tetracycline Side Effects:** Remember the "3 Ds": **D**entition (permanent tooth discoloration), **D**evelopment (bone growth inhibition), and **D**iarrhea (due to alteration of normal gut flora—a common complication of broad-spectrum therapy). * **Drug of Choice:** Tetracyclines (specifically Doxycycline) remain the drug of choice for Rickettsial infections, Chlamydia, and Cholera. * **Contraindication:** Avoid in pregnancy and children under 8 years of age.

Q: Which drug does NOT cause hemolysis in a patient with G6PD deficiency?

Chloroquine. **Explanation:** Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is an X-linked recessive disorder where RBCs lack the ability to regenerate reduced glutathione, making them highly susceptible to oxidative stress. When exposed to certain oxidizing drugs, hemoglobin precipitates into **Heinz bodies**, leading to hemolysis. **Why Chloroquine is the correct answer:** While Chloroquine is an antimalarial, it is considered **safe** in standard therapeutic doses for G6PD-deficient individuals. It does not possess significant oxidizing potential compared to other drugs in its class. In contrast, its cousin **Primaquine** is the classic prototype for drug-induced hemolysis in these patients. **Analysis of Incorrect Options:** * **Primaquine (Option A):** This is the most high-yield trigger. It is an 8-aminoquinoline that causes significant oxidative stress. G6PD testing is mandatory before prescribing Primaquine for the radical cure of *P. vivax*. * **Nalidixic Acid (Option C):** A first-generation quinolone known to trigger hemolytic anemia in G6PD-deficient patients. * **Nitrofurantoin (Option D):** Commonly used for UTIs, this drug is a well-documented oxidizing agent that must be avoided in these patients. **NEET-PG High-Yield Pearls:** * **Mnemonic for G6PD Triggers:** "**S**ell **P**ins **A**nd **N**eedles" (**S**ulfonamides, **P**rimaquine, **A**ntipyretics/Dapsone, **N**itrofurantoin/Nalidixic acid). * **Safe Antimalarials:** Chloroquine, Quinine, and Proguanil. * **Diagnosis:** Peripheral smear shows **"Bite cells"** (degmacytes) and **Heinz bodies** (denatured hemoglobin) visualized with supravital stains like Crystal Violet. * **Key Contraindication:** Rasburicase (used in Tumor Lysis Syndrome) is strictly contraindicated in G6PD deficiency.

Question 1

Nightmares are commonly associated with which of the following antiretroviral drugs?

Accepted Answer

Efavirenz

Answer

Indinavir

Answer

Zidovudine

Answer

Tenofovir

Question 2

What are the differences between fluconazole and ketoconazole?

Accepted Answer

All the above

Answer

Duration of action

Answer

Absorption dependency on gastric acidity

Answer

Adverse effects

Question 3

What is the drug of choice for the prevention of infection following an animal bite?

Accepted Answer

Amoxicillin/clavulanate

Answer

Tetracycline

Answer

Ciprofloxacin

Answer

Cotrimoxazole

Question 4

Bleeding is seen with the use of which of the following drugs?

Accepted Answer

Moxalactam

Answer

Cefaloridine

Answer

Cefazolin

Answer

Ceftazidime

Question 5

What is the drug of choice for a sore throat caused by Group A beta-hemolytic Streptococcus?

Accepted Answer

Penicillin

Answer

Erythromycin

Answer

Ceftriaxone

Answer

Sulfonamides

Question 6

The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivatives (artemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except?

Accepted Answer

Artesunate plus quinine

Answer

Artemether plus lumefantrine

Answer

Artesunate plus pyrimethamine-sulfadoxine

Answer

Artesunate plus mefloquine

Question 7

Toxicity of amphotericin B can be reduced by which of the following methods?

Accepted Answer

Incorporation into a liposomal complex

Answer

Administering the drug with dextrose

Answer

Combination with fluconazole

Answer

All of the above

Question 8

Which of the following antimicrobial agents is not effective against anaerobes?

Accepted Answer

Gentamicin

Answer

Cefotetan

Answer

Imipenem

Answer

Clindamycin

Question 9

Which of the following is a broad-spectrum antibiotic?

Accepted Answer

Tetracycline

Answer

Erythromycin

Answer

Streptomycin

Answer

All of the above

Question 10

Which drug does NOT cause hemolysis in a patient with G6PD deficiency?

Accepted Answer

Chloroquine

Answer

Primaquine

Answer

Nalidixic acid

Answer

Nitrofurantoin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?